Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.69 |
| ▸ | HTR2C | P28335 | 2/20 | 0.69 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | OPA1 | O60313 | 1/20 | 0.44 |
| ▸ | EIF5B | O60841 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12450045 | 0.88 | HTR2A (0.74) | HTR2AHTR2CMTNR1AMTNR1BHPGD | |
| SCHEMBL9303578 | 0.82 | HTR2A (0.63) | HTR2AHTR2CMTNR1AMTNR1BHPGD | |
| SCHEMBL10199629 | 0.82 | HTR2A (1.00) | HTR2AHTR2CMTNR1AMTNR1BHPGD | |
| SCHEMBL2260014 | 0.81 | HTR2A (0.65) | HTR2AHTR2CMTNR1AMTNR1BHPGD | |
| SCHEMBL1395857 | 0.81 | MTNR1A (0.61) | HTR2AHTR2CMTNR1AMTNR1BHPGD | |
| SCHEMBL12572732 | 0.80 | HTR2A (0.60) | HTR2AHTR2CMTNR1AMTNR1BHPGD | |
| SCHEMBL10100276 | 0.80 | HTR2A (0.59) | HTR2AHTR2CMTNR1AMTNR1BHPGD | |
| SCHEMBL2345293 | 0.79 | HTR2A (0.70) | HTR2AHTR2CMTNR1AMTNR1BHPGD | |
| SCHEMBL2020434 | 0.79 | MTNR1A (0.59) | HTR2AHTR2CMTNR1AMTNR1BHPGD | |
| SCHEMBL2349253 | 0.79 | HTR2A (0.69) | HTR2AHTR2CMTNR1AMTNR1BHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384371-B2 | Hydroxylation of branched aliphatic or aromatic substrates employing the amycolatopsis lurida cytochrome P450 | HYPHA DISCOVERY LIMITED (GB) | 2022-07-12 | — | — | US | disclosed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-8754078-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | TP53, MKI67, POLI | HTR2A 4571/4885HTR2C 4153/4885MTNR1A 1918/4885 |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | HTR2A 4255/4885HTR2C 3384/4885MTNR1A 1569/4885 |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | MKI67, NUP205, TP53 | HTR2A 4255/4885HTR2C 3384/4885MTNR1A 1569/4885 |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | HTR2A 4255/4885HTR2C 3384/4885MTNR1A 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.